“Our study provides novel information on workers’ use of cannabis for their work-related conditions, a population for which little data exist. … Findings of this study demonstrate workers are turning to cannabis many months following the onset of their original work-related condition.”
Recently conducted observational trials in Israel and the United Kingdom have documented improved symptoms following the use of cannabis products among patients with post-traumatic stress. These outcomes include statistically significant changes in sleep quality and in anxiety, fewer nightmares, and improved quality of life.
“These findings contribute robust evidence for clinicians regarding the potential benefits of medical cannabis in reducing the opioid burden for patients receiving long-term opioid therapy and possibly reduc[ing] their risk for overdose.”
“As a cannabis consumer, marijuana has changed my life for the better. … There is nothing that I want to do more than be part of an organization that supports initiatives that advocate on behalf of freedoms for cannabis consumers.”
“The current study revealed the positive effects of MC [medical cannabis] therapy in some patients with FMS [ fibromyalgia syndrome] and resistance to conventional treatment. Thus, cannabinoids may be considered for FMS treatment.”
“The findings of this study add to the growing body of evidence that easier access to cannabis for patients with pain may reduce opioid use and partially offset expenditures for both public and private drug plans.”
“Over time, individuals who continued consuming cannabis within this longitudinal study reported lower pain severity and pain interference scores, as well as improved quality of life and general health symptoms scores.”
Some 30 percent of migraine patients have used cannabis to mitigate migraine pain. Among these users, 82 percent reported it to be effective at providing migraine relief.